Canakinumab: A review of its use in the management of systemic juvenile idiopathic arthritis

BioDrugs

Volumn 29, Issue 2, 2015, Pages 133-142

  Hoy, Sheridan M ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTHRITIS, JUVENILE; HUMAN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, JUVENILE; HUMANS;

EID: 84937758155     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-015-0123-8     Document Type: Article

References (27)

1. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138-49.
2. Gurion R, Lehman TJA, Moorthy LN. Systemic arthritis in children: a review of clinical presentation and treatment. Int J Inflam. 2012;2012(271569).
3. Gowdie PJ, Tse SML. Juvenile idiopathic arthritis. Pediatr Clin N Am. 2012;59(2):301-27.
4. DeWitt EM, Kimura Y, Beukelman T, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res. 2012;64(7):1001-10.
5. Vannucci G, Cantarini L, Giani T, et al. Glucocorticoids in the management of systemic juvenile idiopathic arthritis. Paediatr Drugs. 2013;15(5):343-9.
6. Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin Pharmacokinet. 2012;51(6):e1-18.
7. European Medicines Agency. Ilaris (canakinumab): summary of product characteristics. 2014. http://www.ema.europa.eu/ema/. Accessed 16 March 2015.
8. Curran MP. Canakinumab. BioDrugs. 2012;26:53-9.
9. European Medicines Agency. Ilaris (canakinumab): assessment report. 2013. http://www.ema.europa.eu/ema/. Accessed 16 March 2015.
10. Novartis Pharmaceuticals Corporation. ILARIS (canakinumab) injection for subcutaneous use: prescribing information. 2013. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed 16 March 2015.
11. Wulffraat N, Brunner HI, Ruperto N, et al. Analysis of biomarkers in systemic juvenile idiopathic arthritis patients on canakinumab therapy (abstract no. 761). Arthritis Rheum. 2012;64(10 Suppl.):S328.
12. Nirmala NR, Wulffraat N, Brunner H, et al. Characterization of changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy (abstract no. 1692). Arthritis Rheum. 2013;65(10 Suppl.):S716.
13. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396-406.
14. Brunner H, Quartier P, Constantin T, et al. Canakinumab in the treatment of systemic juvenile idiopathic arthritis: results from a 12-week pooled post-hoc analysis for efficacy (abstract no. 270). Arthritis Rheum. 2013;65(10 Suppl.):S112-3.
15. Wulffraat NM, Ruperto N, Brunner HI, et al. Response to canakinumab treatment is maintained in systemic juvenile idiopathic arthritis patients (abstract no. 931). Arthritis Rheumatol. 2014;66(10 Suppl):S413-4.
16. Ruperto N, Brunner H, Constantin T, et al. Baseline characteristics of patients with active systemic JIA successfully discontinuing corticosteroid while receiving canakinumab: secondary analysis from a pivotal phase 3 trial (abstract no. OP0136). Ann Rheum Dis. 2013;72(Suppl. 3):97.
17. Schneider R, Brunner HI, Ruperto N, et al. Marked improvement in patient reported outcomes of children with active systemic juvenile idiopathic arthritis with canakinumab treatment: results of the phase III program (abstract no. 269). Arthritis Rheum. 2013;65(10 Suppl.):S111-2.
18. Wulffraat N, Kallinich T, McCann L, et al. Changes in health-related quality of life in systemic juvenile idiopathic arthritis patients after single dose of canakinumab (abstract no. THU0328). Ann Rheum Dis. 2012;71(Suppl. 3):266.
19. Brunner HI, Ruperto N, Koné-Paut I, et al. An exploratory analysis of predictors of response from 12-weeks of canakinumab therapy in patients with active systemic juvenile idiopathic arthritis (abstract no. 930). Arthritis Rheumatol. 2014;66(Suppl. 10):S413.
20. Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64(2):557-67.
21. Xiong Y, Wang W, Ebling W, et al. Exposure-response modelling of canakinumab in the avoidance of flares in children with systemic juvenile idiopathic arthritis (abstract no. 2029). Arthritis Rheum. 2013;65(10 Suppl.):S865-6.
22. Kimura Y, Weiss JE, Haroldson KL, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res. 2013;65(5):745-52.
23. Levi M, Dumortier T, Ruperto N, et al. A pharmacometric based analysis of the occurrence of selected safety events of special interest and canakinumab exposure in systemic juvenile idiopathic arthritis patients (abstract no. 2295). Arthritis Rheumatol. 2014;66(10 Suppl):S1001-2.
24. Grom AA, Brunner HI, Ruperto N, et al. Canakinumab in systemic juvenile idiopathic arthritis: impact on the rate and clinical presentation of macrophage activation syndrome (abstract no. FRI0528). Ann Rheum Dis. 2014;73(Suppl. 2).
25. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res. 2013;65(10):1551-63.
26. Otten MH, Anink J, Spronk S, et al. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann Rheum Dis. 2013;72(11):1806-12.
27. Kimura Y, DeWitt EM, Beukelman T, et al. Adding canakinumab to the Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for systemic juvenile idiopathic arthritis: comment on the article by DeWitt et al. Arthritis Care Res. 2014;66(9):1430-1.